11:30 am Leveraging FGF21 Signaling to Target Fibrosis & Metabolic Pathways for More Effective Treatment Development
Time: 11:30 am
day: Combination & Sequential Therapy Focus Day
Details:
- Using FGF21 therapy as a potent modulator of fibrosis progression and regression across cirrhotic and non-cirrhotic patients
- Evaluating the effect of FGF21 analogs on hepatic steatosis and inflammation reduction to improve the underlying drivers of fibrosis
- Examining additive effects when combined with incretin therapies to provide a holistic approach to therapy
